Pharmaceutical giant Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for $1 billion ...

We recently compiled a list of the Jim Cramer Discussed These 11 Stocks Recently. In this article, we are going to take a ...

Joseph J. Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson (NYSE:JNJ), recently executed significant stock transactions according to a recent SEC filing. On February 7, ...

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. Furthermore, revenue ...

Johnson & Johnson (NYSE:JNJ) researches, develops, manufactures and sells various products in the health care field worldwide. It is set to report its Q1 2025 earnings on April 15. Wall Street ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Johnson & Johnson is expected to post earnings ...

Johnson & Johnson (NYSE: JNJ ... s top-selling drugs is now facing biosimilar competition, weighing on its stock price growth lately. If you want upside with a smoother ride than an individual ...

Johnson & Johnson (NYSE:JNJ) has had a rough three months with its share price down 11%. However, stock prices are usually driven by a company’s financials over the long term, which in this case ...